Biofrontera Inc.
1.0700+0.01 (+0.94%)
Oct 30, 4:00:00 PM EDT · NasdaqCM · BFRI · USD
Key Stats
Market Cap
11.42MP/E (TTM)
-Basic EPS (TTM)
-1.82Dividend Yield
0%Recent Filings
8-K
Biofrontera closes Ameluz asset deal
Biofrontera Inc. closed its restructuring and asset purchase agreement with Biofrontera AG on October 23, 2025, acquiring full U.S. rights to Ameluz and RhodoLED, including the NDA, patents, manufacturing, and personnel. The deal slashes earnout payments to 12%-15% of U.S. net sales from the prior 25%-35%, boosting margins while securing an $11 million investor infusion—$2.5 million released at close—to drive profitability. Asset transfer wraps by early 2026. This sharpens operations but hinges on sales growth amid clinical uncertainties.
8-K
Q2 revenues surge 15%
Biofrontera Inc. reported Q2 2025 revenues of $9.0 million, up 15% from $7.8 million in 2024, fueled by 9.5% higher Ameluz sales volume and 5% better pricing, while cost of revenues plunged 41.8% to $2.4 million thanks to a revamped deal with Biofrontera AG. This restructuring hands the company U.S. IP, NDA, and manufacturing control for Ameluz and RhodoLED, slashing royalties to 12-15% from 25-35%, backed by $11 million in fresh funding. Cash climbed to $7.2 million. Yet net loss widened to $5.3 million amid $3.4 million in legal hits.
10-Q
Q2 FY2025 results
Biofrontera's Q2 revenue climbed 15.3% y/y to $9.0M, fueled by 9.5% higher Ameluz volume and 5% better pricing, while YTD sales rose 12.0% to $17.6M; gross margins expanded sharply as related-party costs dropped 41.8% y/y to $2.4M, thanks to the amended license deal, yet operating losses held steady at $5.1M amid surging legal fees from patent disputes. Diluted EPS worsened to -$0.57 from -$0.05, confirmed against 9.4M weighted shares with no anti-dilution noted. Cash swelled to $7.2M on $8.5M stockholder advances for a pending Series C raise, supporting a strategic buyout of U.S. Ameluz rights via 3,019 Series D shares (expected close September 2025, 12% royalty). Free cash flow not disclosed in the 10-Q. Nasdaq compliance hangs in the balance.
8-K
Biofrontera appoints commercial chief
Biofrontera Inc. appointed George Jones as Chief Commercial Officer effective August 25, 2025, to lead sales, marketing, and market access amid its recent acquisition of Ameluz and RhodoLED assets from Biofrontera AG. Jones, with over 25 years in pharma and biotech, including COO at UpScriptHealth since 2021, joins with a $315,000 base salary, up to 50% bonus, and at least 100,000 stock options vesting over three years. This hire bolsters commercial efforts post-royalty cut from 25-35% to 12-15% of net sales, edging the company toward cash break-even. Yet risks like regulatory hurdles loom.
8-K
Biofrontera acquires U.S. rights to Ameluz
Biofrontera Inc. signed an agreement on June 30, 2025, to acquire full U.S. rights to Ameluz and RhodoLED from Biofrontera AG, replacing the prior transfer pricing with royalties of 12% on U.S. Ameluz revenue below $65 million and 15% above, while assuming all U.S. business costs. In exchange, Biofrontera AG receives 3,109 shares of Series D Preferred Stock, granting a 10% post-money equity stake. To fund this, the company launched a $11 million Series C Preferred Stock private placement in two tranches closing July 1 and by September 30, 2025, for acquisition costs and general purposes. Yet stockholder approval remains needed for full conversion rights.
IPO
Employees
Sector
Industry
AMPH
Amphastar Pharmaceuticals, Inc.
24.66+0.42
AMRX
Amneal Pharmaceuticals, Inc.
10.00-0.43
AYTU
Aytu BioPharma, Inc.
2.21+0.03
BHC
Bausch Health Companies Inc.
6.61+0.71
BIIB
Biogen Inc.
149.61+1.75
BIOA
BioAge Labs, Inc.
7.73+0.05
CBIH
CANNABIS BIOSCIENCE INTERNATION
0.00+0.00
GALDY
GALDERMA GROUP AG
36.82+0.39
NXEN
Nexien BioPharma, Inc.
0.01+0.00
SBFM
Sunshine Biopharma Inc.
1.75-0.01